profit from every A$100 of sales.
A$0A$100
Cochlear
A$151.37-1.05% today
-42.5% in 1 year
1-year low A$90.001-year high A$277.26
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay A$25.45 for every A$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cochlear sold, what it kept, and what it did with the cash.
Sales went from A$1.65 billion in 2022 to A$2.34 billion in 2025, with A$389 million of profit last year.
SalesProfit
Cochlear handed back more cash to shareholders than it generated last year.
A$278M
Free cash flow 2025A$135M
Bought back its own sharesA$28M
Paid as dividendsA$278M
Cash vs. debtA$276M vs. A$236M
Cochlear vs. similar companies
Cochlear grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from A$100 of sales | Sales growth a year | Price per A$1 of profit |
|---|---|---|---|
| Cochlear | 25.5× · Fair price | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Cochlear's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,648 | 1,936 | 2,236 | 2,343 | |
| 1,237 | 1,448 | 1,674 | 1,728 | |
| 296 | 312 | 414 | 406 | |
| 475 | 487 | 579 | 620 | |
| 289 | 301 | 357 | 389 | |
| 4.40 | 4.56 | 5.43 | 5.94 | |
| 75.1% | 74.8% | 74.9% | 73.7% | |
| 18.0% | 16.1% | 18.5% | 17.3% | |
| 17.5% | 15.5% | 16.0% | 16.6% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,465 | 2,569 | 2,745 | 2,825 |
| Cash | 629 | 556 | 514 | 276 |
| Total debt | 254 | 202 | 244 | 236 |
| Total liabilities | 779 | 820 | 905 | 875 |
| 1,686 | 1,749 | 1,841 | 1,950 | |
| 66 | 66 | 66 | 65 | |
| 14.5% | 14.6% | 16.6% | 17.0% | |
| 17.2% | 17.2% | 19.4% | 19.9% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 77 | 96 | 90 | 103 | |
| 299 | 267 | 299 | 135 | |
| Dividends paid | 194 | 197 | 246 | 278 |
| – | 30 | 43 | 28 | |
| – | – | – | – |
Valuation
- 25.5×
- –
- 2.41
- 5.7×
- 4.2×
- 73.3×
- 15.9×
- 1.4%
- 3.9%
- 2.8%
Profitability
- 73.7%
- 17.3%
- 16.6%
- –
- 8.1%
- 14.1%
- –
- –
- –
- –
Growth
- +12.4%
- +10.6%
- –
- –
- −0.2%
Financial health
- 0.1×
- 0.12
- –
- 17.2×
- 2.15
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 39%of 963
Top 31%of 894
Top 47%of 632
Top 43%of 908
Bottom 49%of 991
2.8%of the share price, paid each year
On $1,000 invested$28a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
71.5% of its profit
Room to growStretchedMore than it earns: 206.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
52No pass
Philip Fisher
68Pass
Peter Lynch
45No pass
Joel Greenblatt
26No pass
Charlie Munger
64Pass
Terry Smith
62Pass
Questions about Cochlear
Is Cochlear a good stock to buy?
A solid business at a fair price. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cochlear AI analysis
What does Cochlear do?
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It is in Medical Devices, based in Sydney, NSW, Australia, with 5,500 employees.
Does Cochlear pay a dividend?
Yes. At today's price the dividend is 2.8% a year, about 72% of its yearly profit. In 2025 it paid out A$278 million in dividends.
Is Cochlear stock halal?
Yes. Cochlear passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Cochlear stock done over the past year?
Down 42.5% over the past twelve months, to A$151.37. It traded between A$90.00 and A$277.26 and is 45.4% below its high.
Who are Cochlear's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Cochlear's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.